

SUB
E1

D1

1. (Twice Amended) A neuronal cell line obtained from a transgenic rat, the cells of which comprise:
- (i) a conditional oncogene, transforming gene or immortalizing gene or a cell cycle affecting gene operably linked to
 - (ii) a cell type specific promoter.

D2

4. (Twice Amended) F The cell line of claim 1 in which the cell type specific promoter is a human NF-L gene promoter.

D3

6. (Twice Amended) The cell line of claim 1 or 4 in which the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene.

SUB
E2

7. (Twice Amended) The cell line of claim 1 or 4 in which the conditional oncogene, transforming gene, immortalising gene or the cell cycle affecting gene is a C Erb $\beta 2$ gene or a TGF α gene.

D4

19. (Twice Amended) A method of testing a material suspected of being a carcinogen, said method comprising subjecting a rat according to claim 17 or 18 to said material and detecting neoplasms as an indication of carcinogenicity.

20. (Twice Amended) A method of testing a material suspected of conferring protection against the development of neoplasms, said method comprising administering said material to a rat according to claim 17 or 18 and detecting a reduced incidence of development or neoplasms, compared to an untreated rat, as an indication of said protection.

SUB
D5 E7

30. (New) The method of claim 13 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb β 2 gene or a TGF α gene and wherein the cell type specific promoter is a human NF-L gene promoter.

31. (New) The transgenic rat of claim 18 wherein the cell type specific promoter is a human NF-L gene promoter.

SUB
E8

32. (New) The method of claim 25 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb β 2 gene or a TGF α gene and wherein the cell type specific promoter is a human NF-L gene promoter.

REMARKS

Before amendment, claims 1, 3-4, 6-9, 13 and 15-29 were pending. After amendment, claims 1, 4, 6-9, 13 and 15-32 are pending.

A marked up of the claims indicating the changes made as a result of this amendment is attached.

Claim Objections

Claims 19 and 20 are objected to under 37 CFR § 1.75(c) as being in improper multiple dependent form. The claims have been amended. Accordingly, applicants believe that the objection has been obviated.